Experimental autoimmune encephalomyelitis (EAE) as a model for multiple  sclerosis (MS)

Author(s): Constantinescu CS, Farooqi N, O'Brien K, Gran B


Experimental autoimmune encephalomyelitis (EAE) is the most commonly used experimental model for the human inflammatory demyelinating disease, multiple sclerosis (MS). EAE is a complex condition in which the interaction between a variety of immunopathological and neuropathological mechanisms leads to an approximation of the key pathological features of MS: inflammation, demyelination, axonal loss and gliosis. The counter-regulatory mechanisms of resolution of inflammation and remyelination also occur in EAE, which, therefore can also serve as a model for these processes. Moreover, EAE is often used as a model of cell-mediated organ-specific autoimmune conditions in general. EAE has a complex neuropharmacology, and many of the drugs that are in current or imminent use in MS have been developed, tested or validated on the basis of EAE studies. There is great heterogeneity in the susceptibility to the induction, the method of induction and the response to various immunological or neuropharmacological interventions, many of which are reviewed here. This makes EAE a very versatile system to use in translational neuro- and immunopharmacology, but the model needs to be tailored to the scientific question being asked. While creating difficulties and underscoring the inherent weaknesses of this model of MS in straightforward translation from EAE to the human disease, this variability also creates an opportunity to explore multiple facets of the immune and neural mechanisms of immune-mediated neuroinflammation and demyelination as well as intrinsic protective mechanisms. This allows the eventual development and preclinical testing of a wide range of potential therapeutic interventions.

Similar Articles

SOD1 and amyotrophic lateral sclerosis: mutations and  oligomerization

Author(s): Banci L, Bertini I, Boca M, Girotto S, Martinelli M, et  al.

Oral treatment  for multiple sclerosis

Author(s): Killestein J, Rudick RA, Polman CH

Variable effects of cyclophosphamide in rodent models of  experimental allergic encephalomyelitis

Author(s): Mangano K, Nicoletti A, Patti F, Donia M, Malaguarnera L,  et al.

[Study of cellular immunity and the opioid peptide system in patients  with multiple sclerosis]

Author(s): Demina TL, BoÄ­ko AN, Rossel's AN, Balashov KE, Popova NF 

Critical role of preproenkephalin in experimental autoimmune  encephalomyelitis

Author(s): Weir C1, McNeill A, Hook S, Harvie M, La Flamme AC, et al. 

The immunoregulatory abilities of polymorphonuclear neutrophils in  the course of multiple sclerosis

Author(s): Ziaber J, PaÅ›nik J, Baj Z, Pokoca L, Chmielewski H, et  al.

Structural analysis of neprilysin with various specific and potent inhibitors

Author(s): Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE

The biology  of the opioid growth factor receptor (OGFr)

Author(s): Zagon IS, Verderame MF, McLaughlin PJ

Opioid growth factor suppresses expression of experimental autoimmune  encephalomyelitis

Author(s): Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ